Cambridge Study Explores Dual Mechanisms of GIP Receptor in Weight Loss
Researchers at the University of Cambridge have made significant strides in understanding how the glucose-dependent insulinotropic polypeptide receptor (GIPR) can be targeted in two opposing ways to promote weight loss. Their study, published in Nature Metabolism, reveals that the effectiveness of GIPR modulation depends on the specific brain region being targeted. Activating GIPR in the brainstem has been shown to reduce appetite, while blocking the same receptor in the hypothalamus achieves weight loss through a different mechanism.
With over a billion individuals worldwide living with obesity—a condition linked to increased risks of type 2 diabetes, cardiovascular diseases, and cancer—effective weight loss strategies are crucial. Traditional methods, such as diet and exercise, often prove insufficient for substantial weight loss.
The emergence of modern weight loss medications has provided new avenues for treatment, particularly those that act on specific receptors involved in appetite regulation. Medications like Wegovy and Ozempic work by activating the glucagon-like peptide 1 receptor (GLP-1R), while others, such as Mounjaro and Zepbound, target GIPR. Interestingly, some drugs activate GIPR, while others block it, leading to the question of how both approaches can be effective despite their opposing actions.
To investigate this, the Cambridge team conducted experiments with genetically engineered mice, selectively removing GIPR from specific brain areas. They compared groups of mice lacking GIPR in the brainstem and hypothalamus with a control group. The results indicated that GIPR agonists primarily function in the brainstem, leading to reduced appetite and lower body weight. Conversely, GIPR antagonists promoted weight loss through the hypothalamus, where GIPR acts as a brake on the brain's response to fullness signals. By blocking GIPR, this brake is released, enhancing the effectiveness of satiety signals.
Additionally, the researchers noted that blocking GIPR could amplify the effects of other obesity medications targeting the amylin receptor. This suggests that GIPR antagonists might play a role in enhancing various obesity treatments. The findings also shed light on the potential of combining GIPR antagonism with GLP-1 receptor agonism, as seen in the phase 3 clinical trials of MariTide, a drug that employs both mechanisms.
Dr. Jo Lewis, the study's lead author, emphasized the importance of understanding which brain circuits respond to these medications and how they interact. This knowledge could lead to the development of more effective obesity drugs with fewer side effects, potentially allowing for better combinations of existing treatments. The research was funded by the Medical Research Council and Wellcome, highlighting the ongoing efforts to tackle obesity through innovative scientific approaches.




